<DOC>
	<DOCNO>NCT00558727</DOCNO>
	<brief_summary>This Phase 1 , nonrandomized , open-label , dose-escalation study 3-hour IV infusion RH-1 administer patient advance solid tumor non-Hodgkin 's lymphoma ( NHL ) . Treatment continue patient meet criteria discontinuation .</brief_summary>
	<brief_title>Study RH-1 Patients With Advanced Solid Tumors Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>1 . Histologically proven advance solid tumor NHL , relapse refractory conventional treatment , conventional therapy exists consider acceptable patient . 2 . Tumor accessible biopsy ( require expand cohort 24 patient ; optional patient ) . 3 . At least 18 year age . 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 5 . Life expectancy ≥ 3 month . 6 . Adequate hematological , hepatic , renal function define follow : absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L , platelet count ≥ 100 x 109/L , total bilirubin ≤ 1.5 × upper limit normal ( ULN ) , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2.5 × ULN ( AST/ALT ≤ 5 × ULN document hepatic involvement ) , creatinine ≤ 1.5 mg/dL serum creatinine elevate patient calculate creatinine clearance ≥ 50 mL/min . 7 . Toxic manifestation previous treatment ( ) resolve , exception ≤ Grade 2 fatigue stable &gt; 2 month , ≤ Grade 2 alopecia and/or Grade 1 toxicity , opinion investigator exclude patient ( eg , palmar erythema ; stable Grade 1 peripheral neuropathy ) . 8 . Women childbearing potential must negative serum pregnancy test within 14 day prior first day study treatment . Women postmenopausal least 1 year ( define &gt; 12 month since last menses ) surgically sterilize require test . Women childbearing potential male partner must agree practice medically acceptable contraceptive regimen study treatment initiation least 30 day last administration RH1 . Adequate method contraception double barrier method ( condom spermicidal jelly foam , diaphragm spermicidal jelly foam ) , oral , depot injectable contraceptive , intrauterine device ( IUD ) . RH1 administer woman breast feeding . 9 . Men surgically sterile must agree practice medically acceptable contraceptive regimen study treatment initiation least 90 day last administration RH1 . 10 . Given write informed consent ( IC ) . 1 . Active concurrent malignancy , exception adequately treat carcinoma situ cervix and/or basal squamous cell carcinoma skin . If history prior malignancy , patient must diseasefree ≥ 5 year . 2 . Receipt investigational conventional chemotherapy , target therapy , endocrine therapy , immunotherapy within 4 week prior study treatment plan use course study . Hormonal therapy ( gonadotropinreleasing hormone analog [ leuprolide ] prostate cancer , somatostatin analog [ octreotide ] carcinoid tumor , antiestrogens breast cancer ) allow drug administration stable ≥ 4 week . 3 . Use radiation therapy ( RT ) within 28 day prior study treatment plan use course study . 4 . Requires therapeutic level anticoagulation therapy . 5 . Failed treatment bone marrow transplant . 6 . Active uncontrolled infection , underlie medical condition patient poor medical risk nonmalignant systemic disease , serious illness would impair ability patient receive protocol treatment . 7 . Known positive Hepatitis B , Hepatitis C , human immunodeficiency virus ( HIV ) . 8 . Symptomatic central nervous system ( CNS ) metastases lesion treatment require . 9 . Major surgery within 4 week plan start treatment . 10 . Previous exposure RH1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Advanced Solid Tumors</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>Tumor</keyword>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Benzoquinone</keyword>
</DOC>